Peroxisome proliferator-activated receptor ligands reduce aortic dilatation in a mouse model of aortic aneurysm.

[1]  S. Takai,et al.  Effects of chymase inhibitor on angiotensin II-induced abdominal aortic aneurysm development in apolipoprotein E-deficient mice. , 2009, Atherosclerosis.

[2]  R. Willette,et al.  Antioxidative, Antinitrative, and Vasculoprotective Effects of a Peroxisome Proliferator–Activated Receptor-&ggr; Agonist in Hypercholesterolemia , 2003, Circulation.

[3]  Amir Gamliel,et al.  A SUMOylation-dependent pathway mediates transrepression of inflammatory response genes by PPAR-γ , 2005, Nature.

[4]  J. Golledge,et al.  Atvb in Focus Abdominal Aortic Aneurysms: Pathophysiological Mechanisms and Clinical Implications Abdominal Aortic Aneurysm Pathogenesis and Implications for Management , 2022 .

[5]  Julie H. Campbell,et al.  Interaction between Angiotensin II, Osteoprotegerin, and Peroxisome Proliferator-Activated Receptor-γ in Abdominal Aortic Aneurysm , 2008, Journal of Vascular Research.

[6]  M. Voskuil,et al.  Local Monocyte Chemoattractant Protein-1 Therapy Increases Collateral Artery Formation in Apolipoprotein E–Deficient Mice but Induces Systemic Monocytic CD11b Expression, Neointimal Formation, and Plaque Progression , 2003, Circulation research.

[7]  Satinder K. Singh,et al.  Subtherapeutic Dose of Pioglitazone Reduces Expression of Inflammatory Adipokines in db/db Mice , 2009, Pharmacology.

[8]  J. Golledge,et al.  Whole genome expression analysis within the angiotensin II-apolipoprotein E deficient mouse model of abdominal aortic aneurysm , 2009, BMC Genomics.

[9]  M. Linton,et al.  Transiently heightened angiotensin II has distinct effects on atherosclerosis and aneurysm formation in hyperlipidemic mice. , 2006, Atherosclerosis.

[10]  P. Buttner,et al.  Assessment of a Serum Assay for Quantification of Abdominal Aortic Calcification , 2006, Arteriosclerosis, thrombosis, and vascular biology.

[11]  J. Rutledge,et al.  17 Beta-estradiol attenuates development of angiotensin II-induced aortic abdominal aneurysm in apolipoprotein E-deficient mice. , 2003, Arteriosclerosis, thrombosis, and vascular biology.

[12]  W. Xie,et al.  Preventive effects of fenofibrate on insulin resistance, hyperglycaemia, visceral fat accumulation in NIH mice induced by small-dose streptozotocin and lard. , 2007, Pharmacological research.

[13]  S. Weiss,et al.  Gender Differences in Experimental Aortic Aneurysm Formation , 2004, Arteriosclerosis, thrombosis, and vascular biology.

[14]  D. Bruemmer,et al.  PPARalpha agonists suppress osteopontin expression in macrophages and decrease plasma levels in patients with type 2 diabetes. , 2007, Diabetes.

[15]  A. Daugherty,et al.  Differential Effects of Doxycycline, a Broad-Spectrum Matrix Metalloproteinase Inhibitor, on Angiotensin II–Induced Atherosclerosis and Abdominal Aortic Aneurysms , 2003, Arteriosclerosis, thrombosis, and vascular biology.

[16]  D. Bruemmer,et al.  PPARα Agonists Suppress Osteopontin Expression in Macrophages and Decrease Plasma Levels in Patients With Type 2 Diabetes , 2007, Diabetes.

[17]  Robert W. Thompson,et al.  Treatment With Simvastatin Suppresses the Development of Experimental Abdominal Aortic Aneurysms in Normal and Hypercholesterolemic Mice , 2005, Annals of surgery.

[18]  W. Garvey,et al.  Administration of Pioglitazone in Low-Density Lipoprotein Receptor-Deficient Mice Inhibits Lesion Progression and Matrix Metalloproteinase Expression in Advanced Atherosclerotic Plaques , 2006, Journal of cardiovascular pharmacology.

[19]  Lufei Hu,et al.  Differential effects of angiotensin II on atherogenesis at the aortic sinus and descending aorta of apolipoprotein-E-deficient mice. , 2005, American journal of hypertension.

[20]  Y. Chao,et al.  Reduction of Atherosclerosis by the Peroxisome Proliferator-activated Receptor α Agonist Fenofibrate in Mice* , 2002, The Journal of Biological Chemistry.

[21]  Paula Clancy,et al.  Association Between Osteopontin and Human Abdominal Aortic Aneurysm , 2007, Arteriosclerosis, thrombosis, and vascular biology.

[22]  F. Howe,et al.  Rosiglitazone Reduces the Development and Rupture of Experimental Aortic Aneurysms , 2009, Circulation.

[23]  R. Ricci,et al.  Regression of abdominal aortic aneurysm by inhibition of c-Jun N-terminal kinase , 2005, Nature Medicine.

[24]  J. Rutledge,et al.  17&bgr;-Estradiol Attenuates Development of Angiotensin II–Induced Aortic Abdominal Aneurysm in Apolipoprotein E–Deficient Mice , 2003 .

[25]  G. Moneta,et al.  Screening for Abdominal Aortic Aneurysm: A Best-Evidence Systematic Review for the U.S. Preventive Services Task Force , 2006 .

[26]  A Daugherty,et al.  Angiotensin II promotes atherosclerotic lesions and aneurysms in apolipoprotein E-deficient mice. , 2000, The Journal of clinical investigation.

[27]  S. Anand,et al.  Immediate repair compared with surveillance of small abdominal aortic aneurysms. , 2002, Vascular medicine.

[28]  D. Denhardt,et al.  Osteopontin: role in immune regulation and stress responses. , 2011, Cytokine & growth factor reviews.

[29]  M. Halks-Miller,et al.  Fasudil, a Rho-Kinase Inhibitor, Attenuates Angiotensin II–Induced Abdominal Aortic Aneurysm in Apolipoprotein E–Deficient Mice by Inhibiting Apoptosis and Proteolysis , 2005, Circulation.

[30]  A. Daugherty,et al.  Aortic Dissection Precedes Formation of Aneurysms and Atherosclerosis in Angiotensin II-Infused, Apolipoprotein E-Deficient Mice , 2003, Arteriosclerosis, thrombosis, and vascular biology.

[31]  L. Oberley,et al.  Vitamin E Inhibits Abdominal Aortic Aneurysm Formation in Angiotensin II–Infused Apolipoprotein E–Deficient Mice , 2004, Arteriosclerosis, thrombosis, and vascular biology.

[32]  W. Hsueh,et al.  Angiotensin II-accelerated atherosclerosis and aneurysm formation is attenuated in osteopontin-deficient mice. , 2003, The Journal of clinical investigation.